Biotech Investing argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada
Biotech Investing argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
Biotech Investing argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
Biotech Investing argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
